Vera Therapeutics (NASDAQ:VERA) CEO Marshall Fordyce Sells 16,925 Shares

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 16,925 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $710,511.50. Following the transaction, the chief executive officer directly owned 257,163 shares of the company’s stock, valued at approximately $10,795,702.74. The trade was a 6.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Vera Therapeutics Price Performance

VERA traded down $0.69 during midday trading on Wednesday, hitting $41.68. 776,869 shares of the company traded hands, compared to its average volume of 897,432. The company has a current ratio of 12.21, a quick ratio of 12.21 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $2.92 billion, a price-to-earnings ratio of -10.45 and a beta of 1.16. Vera Therapeutics, Inc. has a 52-week low of $18.53 and a 52-week high of $56.05. The business has a 50 day simple moving average of $46.63 and a two-hundred day simple moving average of $35.30.

Institutional Investors Weigh In On Vera Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. GAMMA Investing LLC boosted its holdings in Vera Therapeutics by 50.5% during the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after acquiring an additional 236 shares during the period. Optimize Financial Inc lifted its position in shares of Vera Therapeutics by 1.5% during the fourth quarter. Optimize Financial Inc now owns 17,800 shares of the company’s stock worth $901,000 after purchasing an additional 256 shares in the last quarter. Virtus Investment Advisers LLC boosted its stake in shares of Vera Therapeutics by 5.7% in the fourth quarter. Virtus Investment Advisers LLC now owns 5,342 shares of the company’s stock valued at $271,000 after purchasing an additional 290 shares during the period. Intech Investment Management LLC boosted its stake in shares of Vera Therapeutics by 2.4% in the fourth quarter. Intech Investment Management LLC now owns 17,838 shares of the company’s stock valued at $903,000 after purchasing an additional 424 shares during the period. Finally, Invesco Ltd. grew its holdings in shares of Vera Therapeutics by 2.0% in the second quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock valued at $656,000 after purchasing an additional 550 shares in the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Wall Street Analyst Weigh In

VERA has been the subject of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vera Therapeutics in a research note on Wednesday, November 26th. JPMorgan Chase & Co. lowered their target price on Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating on the stock in a report on Friday, December 19th. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price target on shares of Vera Therapeutics in a report on Friday, November 28th. Evercore increased their price target on Vera Therapeutics from $75.00 to $97.00 and gave the company an “outperform” rating in a report on Monday, December 8th. Finally, The Goldman Sachs Group boosted their price objective on Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Nine analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $77.18.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.